Sanara MedTech Inc. (SMTI), a medical technology company, on Monday released its first quarter financial results.
The company specializes in the development and commercialization of technologies that improve clinical outcomes and reduce healthcare expenditures in the surgical market.
Q1 2026:
The company recorded net revenues of $27.79 million, 19% higher than the $23.43 million reported a year ago. This included revenues from soft tissue repair products equaling $24.94 million, and $2.85 million from bone fusion products.
Gross profits accounted for 93% of revenue, amounting to $25.87 million, higher than the $21.59 million gained in the first quarter of 2025.
Sanara recorded net income from continuing operations of $0.4 million, or $0.04 per share in Q1, 2026, reversing a net loss from continuing operations of $0.6 million, or $0.07 per share, in the first quarter of 2025.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were $4.3 million in the first quarter, compared to the EBITDA of $2.7 million in the previous year.
Cash, cash equivalents, and marketable securities held by the company on March 31, 2026, amounts to $13.59 million.
SMTI closed Monday at $18.02, down 2.07%. In the overnight market, the stock is trading at $20.42, up 13.32%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.